
    
      CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or
      refractory B-cell malignancies, CD19 and CD22 are proteins usually expressed on the surface
      of the lymphoma cells. The dual specificity CAR enables the T-cells to recognize and kill the
      tumor cell through recognition of CD19 and CD22.
    
  